This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

NCT03635099 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

274

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Placebo (fasted)
DRUG: BI 25 mg (fasted)
DRUG: BI 50 mg (fasted)
DRUG: BI 100 mg (fasted)
DRUG: BI 200 mg (fasted)
DRUG: Placebo (fed)
DRUG: BI 400 mg once daily (fed)
DRUG: BI 200 mg twice daily, 400 mg total (fed)

Sponsor

Boehringer Ingelheim